trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can
Company profile
Ticker
TRVI
Exchange
Website
CEO
Jennifer L. Good
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
450834299
TRVI stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
20 Mar 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
20 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
EFFECT
Notice of effectiveness
16 Aug 23
CORRESP
Correspondence with SEC
14 Aug 23
S-3/A
Shelf registration (amended)
11 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
Transcripts
TRVI
Earnings call transcript
2023 Q4
20 Mar 24
TRVI
Earnings call transcript
2023 Q3
9 Nov 23
TRVI
Earnings call transcript
2023 Q2
10 Aug 23
TRVI
Earnings call transcript
2023 Q1
11 May 23
TRVI
Earnings call transcript
2022 Q4
16 Mar 23
TRVI
Earnings call transcript
2022 Q3
10 Nov 22
TRVI
Earnings call transcript
2022 Q2
14 Aug 22
TRVI
Earnings call transcript
2022 Q1
14 May 22
TRVI
Earnings call transcript
2021 Q4
17 Mar 22
TRVI
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
4
Christopher Galletta
16 Feb 24
4
Farrell Simon
16 Feb 24
4
David J Clark
16 Feb 24
4
JENNIFER L GOOD
16 Feb 24
4
THOMAS SCIASCIA
16 Feb 24
4
Lisa Delfini
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
Fairmount Funds Management LLC
14 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.97 mm | 25.97 mm | 25.97 mm | 25.97 mm | 25.97 mm | 25.97 mm |
Cash burn (monthly) | (no burn) | 3.38 mm | 3.02 mm | 2.64 mm | 2.43 mm | 2.64 mm |
Cash used (since last report) | n/a | 23.05 mm | 20.53 mm | 17.96 mm | 16.52 mm | 17.98 mm |
Cash remaining | n/a | 2.92 mm | 5.43 mm | 8.01 mm | 9.44 mm | 7.99 mm |
Runway (months of cash) | n/a | 0.9 | 1.8 | 3.0 | 3.9 | 3.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 7 |
Closed positions | 4 |
Increased positions | 13 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 102.69 bn |
Total shares | 77.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
New Enterprise Associates 16 | 14.37 mm | $39.09 mm |
NEA Management | 11.37 mm | $24.79 bn |
Frazier Life Sciences Management | 6.88 mm | $15.00 bn |
Venrock Healthcare Capital Partners II | 6.31 mm | $0.00 |
Rubric Capital Management | 5.68 mm | $12.39 bn |
Fairmount Funds Management | 5.16 mm | $11.26 bn |
Frazier Life Sciences Public Fund | 5.10 mm | $9.69 mm |
Viking Global Investors | 4.40 mm | $9.59 bn |
VR Adviser | 3.42 mm | $7.46 bn |
Rosalind Advisors | 2.19 mm | $1.40 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | David J Clark | Stock Option Common Stock | Grant | Acquire A | No | No | 2.38 | 175,000 | 416.50 k | 175,000 |
15 Feb 24 | Good Jennifer L | Stock Option Common Stock | Grant | Acquire A | No | No | 2.38 | 630,000 | 1.50 mm | 630,000 |
15 Feb 24 | Thomas Sciascia | Stock Option Common Stock | Grant | Acquire A | No | No | 2.38 | 150,000 | 357.00 k | 150,000 |
15 Feb 24 | Christopher Galletta | Stock Option Common Stock | Grant | Acquire A | No | No | 2.38 | 28,500 | 67.83 k | 28,500 |
15 Feb 24 | Farrell Simon | Stock Option Common Stock | Grant | Acquire A | No | No | 2.38 | 175,000 | 416.50 k | 175,000 |
News
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
9 Apr 24
Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
9 Apr 24
Oppenheimer Maintains Outperform on Trevi Therapeutics, Maintains $9 Price Target
21 Mar 24
Trevi Therapeutics: Q4 Earnings Insights
20 Mar 24
Trevi Therapeutics Q4 2023 GAAP EPS $(0.08) Beats $(0.09) Estimate
20 Mar 24
Press releases
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
9 Apr 24
Trevi Therapeutics to Participate in Upcoming April Events
4 Apr 24
Trevi Therapeutics to Participate in Upcoming April Events
4 Apr 24
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
2 Apr 24
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
20 Mar 24